

Haematologica
HAEMATOL/2016/145821
Version 3

Response to treatment with azacitidine in children with advanced
myelodysplastic syndrome prior to hematopoietic stem cell
transplantation

Nicolas Waespe, Machiel Van Den Akker, Robert J. Klaassen, Lani Lieberman, Meredith S. Irwin, Salah S. Ali, Mohamed Abdelhaleem, Bozana Zlateska, Mira Liebman, Michaela Cada, Tal Schechter, and Yigal Dror

Disclosures: C17 Research Network Canada supported this study with a research grant in partnership with the Aplastic Anemia and Myelodysplasia Association of Canada (AAMAC) and Alexion Pharmaceuticals; the Garron Family Cancer Centre and Sears Canada provided a fellowship and travel grant to NW. Publication costs were partly covered through a special contribution by the Aplastic Anemia and Myelodysplasia Association of Canada (AAMAC).

Contributions: NW performed research, data analysis, and wrote the manuscript; MaA and BZ performed data analysis; RK, LL, MI, SA, ML, MC, and TS performed data acquisition; MoA performed hematopathology evaluation; YD supervised the study and wrote the manuscript.